CROs offering Computational & In-Silico Drug Discovery with Peptide
13 published
13 published CROs match Computational & In-Silico Drug Discovery and Peptide.
Locations in this set include United States, China, United Kingdom, India, 30 countries, and 30+ countries.
Capabilities that show up most often in this set: Discovery Research, Medicinal Chemistry, High-Throughput Screening, Target Identification & Validation, and Bioanalysis.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Aurigene Pharmaceutical Services LimitedIntegrated CRO-CDMO with 25+ years of discovery and development expertise across small and large molecules, operating 16 US FDA-inspected cGMP facilities across three manufacturing countries.
Axcelead Drug Discovery Partners, Inc.Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
HitGen Inc.HitGen Inc. provides drug discovery services built on DNA-encoded library (DEL), fragment-based (FBDD/SBDD) and computational platforms for pharmaceutical and biotech clients. The company also offers oligonucleotide CDMO services and reports serving more than 600 clients globally.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
PozeSCAF Inc.Preclinical drug discovery CRO combining proprietary generative AI platform AxDrug with computational chemistry, synthetic chemistry, and in vitro biology to accelerate hit discovery and lead optimization for biotech and pharma clients.
SelvitaSelvita is an integrated drug discovery and development service provider offering comprehensive solutions from target validation through preclinical candidate nomination and clinical manufacturing, with expertise in small molecules, antibodies, and protein degraders.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Taros Chemicals GmbH & Co. KGIndependent chemistry CRO in Dortmund, Germany offering discovery chemistry, custom synthesis, medicinal chemistry, and process development for pharma, biotech, and chemical companies since 1999.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/computational-drug-discovery/peptide.md